Evaluation of the fullerene compound DF-1 as a radiation protector
Authors:
- Aaron P BrownABAaron P Brown
- Eun Joo ChungECEun Joo Chung
- Mary Ellen UrickMUMary Ellen Urick
- William P ShieldIIIWSWilliam P ShieldIII
- Anastasia L SowersASAnastasia L Sowers
- Angela ThetfordATAngela Thetford
- Uma T ShankavaramUSUma T Shankavaram
- James B MitchellJMJames B Mitchell
- Deborah E CitrinDCDeborah E Citrin
Open Access
- 11 May 2010
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 5 (1) , 34
Abstract
Fullerene compounds are known to possess antioxidant properties, a common property of chemical radioprotectors. DF-1 is a dendrofullerene nanoparticle with antioxidant properties previously found to be radioprotective in a zebrafish model. The purpose of this study was to evaluate the radioprotective effects of DF-1 in a murine model of lethal total body irradiation and to assess for selective radioprotection of normal cells versus tumor cells. In vitro radioresponse was evaluated with clonogenic assays with human tumor cells and fibroblast lines in the presence of varying concentrations of DF-1 or vehicle. DNA double strand break induction and repair was evaluated with immunocytochemistry for γH2AX. Lethal total body irradiation was delivered with 137Cs after intraperitoneal delivery of DF-1 or vehicle control. Bone marrow hypoxia was evaluated with piminidazole uptake assessed by flow cytometry. DF-1 provided modest radioprotection of human cancer cell lines and fibroblast cell lines when delivered prior to irradiation (dose modifying factor or 1.1). There was no evidence of selective protection of fibroblasts versus tumor cells. Cells treated with DF-1 at radioprotective doses were found to have fewer γH2AX foci at 1 and 6 hours after irradiation compared to vehicle treated controls. The LD50/30 for C57Bl6/Ncr mice treated with a single 300 mg/kg dose of DF-1 pre-irradiation was 10.09 Gy (95% CI 9.58-10.26) versus 8.29 Gy (95% CI, 8.21-8.32) for control mice. No protective effects were seen with a single 200 mg/kg dose. No increase in pimonidazole uptake was appreciated in bone marrow of mice treated with DF-1 compared to vehicle controls. DF-1 has modest activity as a radiation protector in vivo. There was no evidence of selective protection from irradiation of normal versus tumor cells with DF-1.Keywords
This publication has 38 references indexed in Scilit:
- On the Mechanism of Action of Fullerene Derivatives in Superoxide DismutationChemistry – A European Journal, 2010
- Radiation countermeasure agents: an updateExpert Opinion on Therapeutic Patents, 2009
- Inhaled Multiwalled Carbon Nanotubes Potentiate Airway Fibrosis in Murine Allergic AsthmaAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Antioxidant Single-Walled Carbon NanotubesJournal of the American Chemical Society, 2009
- Radiation Protection by a New Chemical Entity, Ex-Rad™: Efficacy and MechanismsRadiation Research, 2009
- SOD Activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity studyNanomedicine: Nanotechnology, Biology and Medicine, 2008
- Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosisJournal of Clinical Investigation, 2008
- The chemistry and biology of nitroxide compoundsFree Radical Biology and Medicine, 2007
- Sphingosine-1-Phosphate Protects Proliferating Endothelial Cells from Ceramide-Induced Apoptosis but not from DNA Damage–Induced Mitotic DeathCancer Research, 2007
- In vivo Radioprotection by the Fullerene Nanoparticle DF-1 as Assessed in a Zebrafish ModelClinical Cancer Research, 2006